Clinical Trial Update: Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL)/AmpC Enterobacteriaceae [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating temocillin for complicated urinary tract infections caused by ESBL/AmpC Enterobacteriaceae has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urinary Tract Infection

Drugs mentioned

• Temocillin (temocillin)

Snippet

Sponsor: Belpharma s.a. | Conditions: Urinary Tract Infection | Phase 4 | Status: WITHDRAWN